Impact of DAA Therapy on Bone Microarchitecture and Cytokines After HCV Cure

Overview

This study evaluated changes in bone microarchitecture and inflammatory cytokine levels 18 months after hepatitis C virus (HCV) cure with direct-acting antivirals (DAAs). While no significant improvements in bone microarchitecture were observed compared to controls, significant decreases in inflammatory cytokines IL-18 and TNF-α were noted in cured patients.

Background

Chronic HCV infection is associated with lower bone mineral density and increased fracture risk, partly due to inflammation-driven bone remodeling abnormalities. Inflammatory cytokines such as TNF-α, IL-6, and IL-18 contribute to bone loss by inhibiting osteoblasts and stimulating osteoclasts. Direct-acting antiviral therapies achieve high cure rates for HCV, but the extent to which HCV-related inflammation and bone deficits reverse after cure remains unclear. High-resolution peripheral quantitative computed tomography (HR-pQCT) allows detailed assessment of bone microarchitecture beyond traditional DXA.

Data Highlights

Key Findings

• No significant differences in changes in bone microarchitecture by HR-pQCT between cured HCV patients and controls over 18 months.
• Significant decreases in inflammatory cytokines IL-18 and TNF-α in cured HCV patients compared to increases or stable levels in controls.
• No significant change in IL-6 levels between groups over the study period.
• Bone deficits associated with chronic HCV infection may not reverse within 18 months post-cure despite reductions in key inflammatory cytokines.
• Adjustments for age, sex, body composition, and smoking did not alter the lack of bone microarchitecture improvement findings.

Clinical Implications

While DAA therapy effectively reduces systemic inflammation as evidenced by decreased IL-18 and TNF-α, bone microarchitecture deficits may persist beyond 18 months post-HCV cure. Clinicians should consider ongoing bone health monitoring and management in patients cured of HCV, especially those with additional osteoporosis risk factors. Further research is needed to determine if longer-term follow-up or adjunctive therapies can improve bone outcomes after HCV eradication.

Conclusion

Cure of chronic HCV with DAA therapy significantly reduces inflammatory cytokines IL-18 and TNF-α but does not result in measurable improvements in bone microarchitecture within 18 months. These findings highlight the complexity of HCV-related bone disease and the need for continued bone health assessment after viral eradication.

References

1. Authors/Source/2024 -- Impact of Direct-Acting Antiviral Therapy on Bone Microarchitecture and Inflammatory Cytokine Levels Following Resolution of Chronic Hepatitis C Infection